{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+Oral%2C+10+mg", "query": { "intervention": "Dexamethasone Oral, 10 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 182, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+Oral%2C+10+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T15:09:25.665Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05257083", "title": "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stichting European Myeloma Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2023-10-10", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05257083" }, { "nct_id": "NCT04519476", "title": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-11-01", "completion_date": "2023-12-29", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04519476" }, { "nct_id": "NCT02103335", "title": "Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma in Relapse", "Refractory Multiple Myeloma", "Multiple Myeloma" ], "interventions": [ { "name": "pomalidomide", "type": "DRUG" }, { "name": "marizomib", "type": "DRUG" }, { "name": "low-dose dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2014-06-05", "completion_date": "2016-11-30", "has_results": false, "last_update_posted_date": "2017-11-22", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 4, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02103335" }, { "nct_id": "NCT01402284", "title": "Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 45, "start_date": "2011-07-21", "completion_date": "2020-09-24", "has_results": true, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01402284" }, { "nct_id": "NCT00890552", "title": "A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Amyloidosis" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-03-22", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890552" }, { "nct_id": "NCT00083551", "title": "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Recombinant GM-CSF", "type": "DRUG" }, { "name": "Interferon-alpha-2b", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 668, "start_date": "1998-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083551" }, { "nct_id": "NCT02030483", "title": "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-02", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030483" }, { "nct_id": "NCT01615029", "title": "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Part 1 (Dose Escalation): Daratumumab", "type": "DRUG" }, { "name": "Part 2 (Dose Expansion): Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-06-26", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01615029" }, { "nct_id": "NCT02404220", "title": "Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Entospletinib", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "CNS Prophylaxis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-05-06", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02404220" }, { "nct_id": "NCT04447027", "title": "Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-Cell Lymphoma", "Mature T-cell Malignancies", "Peripheral T-Cell Lymphoma", "Relapsed/ Refractory T-cell Malignancies" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration/Biopsy", "type": "PROCEDURE" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "TTE", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-12-17", "completion_date": "2025-12-17", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-29T15:09:25.665Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447027" } ] }